Director/PDMR Shareholding | 23-Mar-2022 | 11:30 | RNS |
Director/PDMR Shareholding | 17-Mar-2022 | 14:40 | RNS |
Board Change | 17-Mar-2022 | 14:20 | RNS |
Acquisition Completion of Triad Life Sciences Inc | 14-Mar-2022 | 07:00 | RNS |
Annual Results | 08-Mar-2022 | 07:00 | RNS |
Non-Executive Director Changes | 28-Feb-2022 | 11:00 | RNS |
Holding(s) in Company | 10-Feb-2022 | 15:15 | RNS |
Acquisition: entry into attractive wound biologics | 28-Jan-2022 | 07:00 | RNS |
Board Committee Changes | 27-Jan-2022 | 11:00 | RNS |
Block Listing Application | 20-Dec-2021 | 08:45 | RNS |
Non-Executive Director appointment | 16-Dec-2021 | 14:00 | RNS |
Chief Financial Officer succession | 09-Dec-2021 | 07:00 | RNS |
Total Voting Rights | 01-Nov-2021 | 15:35 | RNS |
Q3 Trading Update | 29-Oct-2021 | 07:00 | RNS |
Director/PDMR Shareholding | 18-Oct-2021 | 16:30 | RNS |
Currency | UK Pounds |
Share Price | 213.40p |
Change Today | -4.60p |
% Change | -2.11 % |
52 Week High | 293.40p |
52 Week Low | 205.60p |
Volume | 6,968,435 |
Shares Issued | 2,049.79m |
Market Cap | £4,374.25m |
RiskGrade | 96 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 6 |
Buy | 7 |
Neutral | 4 |
Sell | 1 |
Strong Sell | 0 |
Total | 18 |
Latest | Previous | |
---|---|---|
Interim | Final | |
Ex-Div | 22-Aug-24 | 25-Apr-24 |
Paid | 04-Oct-24 | 23-May-24 |
Amount | 1.82¢ | 4.46¢ |
Time | Volume / Share Price |
17:33 | 853 @ 215.43p |
17:33 | 30,090 @ 215.43p |
17:33 | 5,012 @ 215.43p |
17:33 | 285,556 @ 213.52p |
16:35 | 8,001 @ 213.40p |
CEO | Karim Bitar |
Chair | John McAdam |
CFO | Jonny Mason |
You are here: research